Table 3 List of the 47 target genes selected
From: Identification of a three-gene expression signature of poor-prognosis breast carcinoma
Genesa | Genbank accession number | Chromosomal location | Description |
|---|---|---|---|
AR | NM_000044 | Xq11.2-q12 | Androgen receptor |
AREG | NM_001657 | 4q13-q21 | Amphiregulin |
ARHC/RhoC | NM_175744 | 1p13.1 | Ras homolog gene family, member C |
BCL2 | NM_000633 | 18q21.3 | B-cell CLL/lymphoma 2 |
BRCA1 | NM_007294 | 17q21 | Breast cancer 1, early onset |
BRCA2 | NM_000059 | 13q12.3 | Breast cancer 2, early onset |
CAV1 | NM_001753 | 7q31.1 | Caveolin 1 |
CCND1 | NM_053056 | 11q13 | Cyclin D1 |
CCNE1 | NM_001238 | 19q12 | Cyclin E1 |
CD44 | NM_000610 | 11p13 | CD44 antigen |
CDH1 | NM_004360 | 16q22.1 | Cadherin 1 (E-cadherin) |
CGA | NM_000735 | 6q12-q21 | Glycoprotein hormones, alpha polypeptide |
CGB | NM_000737 | 19q13.32 | Chorionic gonadotropin, beta polypeptide |
CP/Ceruloplasmin | NM_000096 | 3q23-q25 | Ceruloplasmin |
CXCL12 | NM_000609 | 10q11.1 | Chemokine (C-X-C motif) ligand 12 |
CXCR4 | NM_003467 | 2q21 | Chemokine (C-X-C motif) receptor 4 |
DNMT3B | NM_006892 | 20q11.2 | DNA (cytosine-5-)-methyltransferase 3 beta |
EGFR/ERBB1 | NM_005228 | 7p12 | Epidermal growth factor receptor |
ERBB2 | NM_004448 | 17q21.1 | ErbB2 |
ERBB3 | NM_001982 | 12q13 | ErbB3 |
ERBB4 | NM_005235 | 2q33.3-q34 | ErbB4 |
ESR1/ERα | NM_000125 | 6q25.1 | Estrogen receptor 1 (alpha) |
ESR2/ERβ | NM_001437 | 14q | Estrogen receptor 2 (beta) |
ETV4/PEA3/E1AF | NM_001986 | 17q21 | Ets variant gene 4 |
HAS2 | NM-005328 | 8q24.12 | Hyaluronan synthase 2 |
HMMR/RHAMM | NM_012484 | 5q33.2-qter | Hyaluronan-mediated mobility receptor |
KRT19 | NM_002276 | 17q21.2 | Keratin 19 |
MKI67 | NM_002417 | 10q25-qter | Antigen identified by monoclonal antibody Ki-67 |
MYC | NM_002467 | 8q24.12-q24.13 | c-myc oncogene |
p14/ARF | NM_058195 | 9p21 | Alternative reading frame p14 (p14ARF) |
p15/CDKN2B | NM_004936 | 9p21 | Cyclin-dependent kinase inhibitor 2B (p15 CDK inhibitor) |
p16/CDKN2A | NM_000077 | 9p21 | Cyclin-dependent kinase inhibitor 2A (p16 CDK inhibitor) |
PGR/PR | NM_000926 | 11q22-q23 | Progesterone receptor |
PLAU/UPA | NM_002658 | 10q24 | Plasminogen activator, urokinase |
PTGS2/COX2 | NM_000963 | 1q25.2-q25.3 | Prostaglandin-endoperoxide synthase 2 |
PTTG1/Securin | NM_004219 | 5q35.1 | Pituitary tumor-transforming 1 |
RB1 | NM_000321 | 13q14.2 | Retinoblastoma 1 |
SERPINB2/PAI2 | NM_002575 | 18q21.3 | Plasminogen activator inhibitor type 2 |
SERPINB5/Maspin | NM_002639 | 18q21.3 | Maspin |
SERPINE1/PAI1 | NM_000602 | 7q21.3-q22 | Plasminogen activator inhibitor type 1 |
SPP1/Osteopontin | NM_000582 | 4q21-q25 | Secreted phosphoprotein 1 |
SRC | NM_005417 | 20q12-q13 | c-src oncogene |
TERT | NM_003219 | 5p15.33 | Telomerase reverse transcriptase |
TFF1/pS2 | NM_003225 | 21q22.3 | Trefoil factor 1 |
TIAM1 | NM_003253 | 21q22.11 | T-cell lymphoma invasion and metastasis 1 |
TOP2A | NM_001067 | 17q21-q22 | Topoisomerase (DNA) II alpha 170 kDa |
XLKD1/LYVE-1 | NM_006691 | 11p15 | Extracellular link domain containing 1 |